The regulatory consequences of last year’s discovery that carcinogenic impurities called nitrosamines tainted a major supplier’s active ingredient for a popular blood pressure medication are becoming clear.
There will be greater scrutiny, more testing and tighter limits not only for that medication, valsartan, but also for other...







